Track topics on Twitter Track topics that are important to you
Press Release – No. 20 / 2019
Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019
Copenhagen, October 28, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, will host a conference call on November 14, 2019 at 4 PM CET / 10 AM EST following the announcement of results through the third quarter of 2019.
Presenting during the call will be President and Chief Executive Officer Emmanuel Dulac, Senior Vice President and Chief Financial Officer Matt Dallas, and Executive Vice President and Chief Medical and Development Officer Adam Steensberg, with remaining members of corporate management in attendance. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are:
Denmark........................... +45 32 72 80 42
United Kingdom........... ..... +44 (0) 844 571 8892
United States............... ..... +1 631 510 7495
France......................... ..... +33 (0) 176700794
Netherlands................. ..... +31 (0) 207143545
A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/mmc/p/yhu6rmnz, and will be accessible on the Investor section of Zealand’s website (www.zealandpharma.com/investor). Participants are advised to register for the webcast approximately 10 minutes before the scheduled start. A recording of the event and a transcript will be available on the Investor section of Zealand’s website after the call.
For further information, please contact:
Lani Pollworth Morvan, Investor Relations and Communication
+45 50 60 37 78, email@example.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...
Bioscience - any of the sciences that deal with living organisms. The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...